Denis Bedoret News Today

EQS-News: Imcyse SA / Key word(s): Study Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis  13.09.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Imcyse Announces Complet...

EQS-News: Imcyse SA / Key word(s): Miscellaneous Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis 22.06.2023 / 10:30 CET/CEST The issuer is solely responsible for the content of this announcement. Imcy...

Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis

Exceeded target enrollment with 110 patients randomized across 28 clinical sites in Europe, the United States and AustraliaEfficacy proof-of-concept data from IMPACT is expected in Q1 2024. Following

EQS-News: Imcyse SA / Key word(s): Study Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes 01.03.2023 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Imcyse Announces Completion of Enrollment in Phase 2 IMPA...

DGAP-News: Imcyse SA / Key word(s): Study 13.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement.   Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis   IMCY-MS-001 study aims to determine safe...

DGAP-News: Imcyse SA / Key word(s): Conference Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference 14.03.2022 / 12:00 The issuer is solely responsible for the content of this announcement. Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference Liège, Belgium, March 14,...

13.01.2022 Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study | Imcyse SA | News | Nachricht | Mitteilung

DGAP-News: Imcyse SA / Key word(s): Personnel Imcyse Appoints Gene Mack, MBA as Chief Financial Officer 03.11.2021 / 13:00 The issuer is solely responsible for the content of this announcement. Imcyse Appoints Gene Mack, MBA as Chief Financial Officer Liège, Belgium, November 3, 2021 - Imcyse, a...

5 (3) Imcyse has raised €21.3 million ($25.8 million) in funding to advance its innovative immunotherapy platform for the treatment of multiple sclerosis (MS) and other severe autoimmune diseases. The funding was a result of a series B financing round featuring existing investors such as Biogenosis, Société Fédérale de Participations et d’Investissement, and the Catholic University of Leuven, as well as the newest investor Pfizer, which took an equity stake as part...